Intraperitoneal chemotherapy for ovarian cancer.

摘要: PURPOSE OF REVIEW Intraperitoneal chemotherapy for ovarian cancer is based on sound pharmacological principles and technically feasible. There mounting evidence, bolstered by a recent randomized trial, that in certain patients, this route of delivery may be superior to traditional intravenous chemotherapy. This review explores the background pharmacokinetic intraperitoneal chemotherapy, evidence supporting an approach, some logistical technical challenges involved. RECENT FINDINGS has been evaluated several settings. Most phase I II data came from second-line treatment cancer, there have few series, including one III exploring consolidation. The greatest impact among studies will large, intergroup trial evaluating therapy front-line setting. study probably change dialogue standard optimally cytoreduced, advanced epithelial cancer. SUMMARY Based findings, should considered women with minimal residual Efforts continue facilitate integration into mainstream practice, future trials designed address lingering controversy surrounding treatment.